Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Topic
Orange Book
Patent/exclusivity records, therapeutic-equivalence codes, reference-listed drugs, and ANDA planning.
Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Policy· June 30, 2026 · 18 min read
FDA Market Exclusivity by the Numbers: Exclusivity and GAIN Registry Analysis
By Ran Chen#Orange Book#Generics#Generic Entry
Generics· June 29, 2026 · 18 min read
Generic Xarelto Entry: Orange Book Patents and NADAC Price Erosion
By Ran Chen#Generics#Orange Book#Generic Entry
Generics· June 27, 2026 · 18 min read
Generic Aubagio Market: ANDA Litigation Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 27, 2026 · 17 min read
Generic Latuda Market: ANDA Exclusivity Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 26, 2026 · 22 min read
Generic Revlimid REMS Launch: Lenalidomide ANDA Entry and NADAC Absence
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM
Generics· June 26, 2026 · 21 min read
Generic Zytiga: Abiraterone Acetate ANDA Saturation and NADAC Pricing
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 25, 2026 · 19 min read
Generic Copaxone: FDA Guidance and NADAC Pricing Dynamics
By Ran Chen#Generics#Orange Book#FDA Approval